NCT03279393View on ClinicalTrials.gov

PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions

PTSDTraumaHealthy

Interventions

DRUG

fluorodeoxyglucose (FDG)-PET/MRI

Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

02114

Massachusetts General Hospital, Boston

All Listed Sponsors

collaborator

Massachusetts General Hospital

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Zahi Fayad

OTHER

NCT03279393 - PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients | Biotech Hunter | Biotech Hunter